Literature DB >> 30902807

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.

Christian Pecquet1,2,3, Ilyas Chachoua1,2, Anita Roy1,2, Thomas Balligand1,2,3, Gaëlle Vertenoeil1,2, Emilie Leroy1,2,3, Roxana-Irina Albu1,2, Jean-Philippe Defour1,2, Harini Nivarthi4, Eva Hug5, Erica Xu5, Yasmine Ould-Amer1,2, Céline Mouton1,2, Didier Colau1,2, Didier Vertommen2, Myat Marlar Shwe1,2, Caroline Marty6,7,8, Isabelle Plo6,7,8, William Vainchenker6,7,8, Robert Kralovics4,9, Stefan N Constantinescu1,2,3.   

Abstract

Calreticulin (CALR) +1 frameshift mutations in exon 9 are prevalent in myeloproliferative neoplasms. Mutant CALRs possess a new C-terminal sequence rich in positively charged amino acids, leading to activation of the thrombopoietin receptor (TpoR/MPL). We show that the new sequence endows the mutant CALR with rogue chaperone activity, stabilizing a dimeric state and transporting TpoR and mutants thereof to the cell surface in states that would not pass quality control; this function is absolutely required for oncogenic transformation. Mutant CALRs determine traffic via the secretory pathway of partially immature TpoR, as they protect N117-linked glycans from further processing in the Golgi apparatus. A number of engineered or disease-associated TpoRs such as TpoR/MPL R102P, which causes congenital thrombocytopenia, are rescued for traffic and function by mutant CALRs, which can also overcome endoplasmic reticulum retention signals on TpoR. In addition to requiring N-glycosylation of TpoR, mutant CALRs require a hydrophobic patch located in the extracellular domain of TpoR to induce TpoR thermal stability and initial intracellular activation, whereas full activation requires cell surface localization of TpoR. Thus, mutant CALRs are rogue chaperones for TpoR and traffic-defective TpoR mutants, a function required for the oncogenic effects.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30902807     DOI: 10.1182/blood-2018-09-874578

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Mutant calreticulin in myeloproliferative neoplasms.

Authors:  Joan How; Gabriela S Hobbs; Ann Mullally
Journal:  Blood       Date:  2019-12-19       Impact factor: 22.113

Review 2.  Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.

Authors:  Ruochen Jia; Robert Kralovics
Journal:  Int J Hematol       Date:  2019-11-18       Impact factor: 2.490

3.  Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN.

Authors:  Aaron T Gerds
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

4.  Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.

Authors:  Manjola Balliu; Laura Calabresi; Niccolò Bartalucci; Simone Romagnoli; Laura Maggi; Rossella Manfredini; Matteo Lulli; Paola Guglielmelli; Alessandro Maria Vannucchi
Journal:  Blood Adv       Date:  2021-04-27

5.  Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.

Authors:  Prithviraj Bose
Journal:  Expert Opin Orphan Drugs       Date:  2019-09-24       Impact factor: 0.694

6.  MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.

Authors:  Shunichiro Yasuda; Satoru Aoyama; Ryoto Yoshimoto; Huixin Li; Daisuke Watanabe; Hiroki Akiyama; Kouhei Yamamoto; Takeo Fujiwara; Yuho Najima; Noriko Doki; Emiko Sakaida; Yoko Edahiro; Misa Imai; Marito Araki; Norio Komatsu; Osamu Miura; Norihiko Kawamata
Journal:  Int J Hematol       Date:  2021-06-24       Impact factor: 2.490

7.  Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development.

Authors:  Thomas Balligand; Younes Achouri; Christian Pecquet; Gilles Gaudray; Didier Colau; Eva Hug; Yacine Rahmani; Vincent Stroobant; Isabelle Plo; William Vainchenker; Robert Kralovics; Benoît J Van den Eynde; Jean-Philippe Defour; Stefan N Constantinescu
Journal:  Leukemia       Date:  2019-08-30       Impact factor: 11.528

8.  Roles of Calreticulin in Protein Folding, Immunity, Calcium Signaling and Cell Transformation.

Authors:  Arunkumar Venkatesan; Leslie S Satin; Malini Raghavan
Journal:  Prog Mol Subcell Biol       Date:  2021

Review 9.  MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment.

Authors:  Julian Grabek; Jasmin Straube; Megan Bywater; Steven W Lane
Journal:  Cells       Date:  2020-08-14       Impact factor: 6.600

Review 10.  Calreticulin and cancer.

Authors:  Jitka Fucikova; Radek Spisek; Guido Kroemer; Lorenzo Galluzzi
Journal:  Cell Res       Date:  2020-07-30       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.